United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read General business news Wanbury Limited reports 11.6% growth in revenue for Q2 FY25, EBITDA surges 19.6% Wanbury Limited, a leading pharmaceutical company with a global footprint in active pharmaceutical ingredients (APIs) and domestic branded… byPallavi MadhirajuNovember 16, 2024